# CJC-1295 Ipamorelin: An Evidence-Appraisal Review of the Research > CJC-1295 Ipamorelin pairs a long-acting GHRH analogue with a selective secretagogue. A cited review of the measured findings, the DAC distinction, the reported effects, and the open questions. A calibrated, cited review of the single-component findings, the DAC-versus-no-DAC distinction, and the one fact the marketing leaves out: the fixed blend itself has never been trialed. ## Start here **CJC-1295 Ipamorelin** is two research peptides used together. CJC-1295 is a long-acting copy of a natural hormone (GHRH) that tells the pituitary gland to make growth hormone. Ipamorelin is a different peptide that nudges the same gland through a separate switch, the one your body's hunger hormone (ghrelin) uses. Because the two work through different doors into the same cell, combining them produces a bigger growth-hormone pulse than either one alone. Here is the honest part. Neither peptide is approved as a medicine, and the **fixed blend has never been tested in a human trial**. What we know comes from studies of each peptide on its own, plus older work showing this *type* of pairing adds up. People who use it report deeper sleep, faster recovery, more appetite, and sometimes water puffiness or a flush after injecting — anecdotal, not proof. What people report, including the downsides, is on [the effects page](/effects). Everything below is study-attributed, with no dosing advice. ## What the CJC-1295 and ipamorelin literature has actually measured A single subcutaneous dose of CJC-1295 (the DAC form) raised mean plasma growth hormone (GH) 2- to 10-fold for six days or more and insulin-like growth factor 1 (IGF-1, the downstream hormone GH makes the liver release) 1.5- to 3-fold for nine to eleven days in healthy adults; after repeated doses IGF-1 stayed above baseline for up to 28 days [1]. That multi-day profile is the defining feature of the CJC-1295 arm. Ipamorelin is the first *selective* GH secretagogue. Unlike the earlier peptides GHRP-6 and GHRP-2, it did not raise ACTH or cortisol (stress hormones) above GHRH-stimulated levels even at doses more than 200 times the amount needed to release GH, while matching GHRP-6's GH output in swine [2]. That selectivity is why ipamorelin is the favored partner peptide. The rationale for putting them together is older than either compound. In normal men, submaximal doses of a GH-releasing peptide combined with GHRH stimulated GH release synergistically — the two acting through independent mechanisms [3]. At the receptor level, co-activating the cloned ghrelin and GHRH receptors in cultured cells produced a cAMP signal roughly twice that of the GHRH receptor alone [4]. So the *idea* of the stack is well grounded. The specific fixed-ratio product is not. ## The DAC distinction most write-ups get wrong "CJC-1295" is not one thing. The *with-DAC* version carries a Drug Affinity Complex — a small chemical handle that covalently bonds to albumin (a carrier protein in blood) and stretches the half-life to several days [5]. The *no-DAC* version, properly called [cjc 1295 dac](/cjc-1295-dac)'s counterpart **Mod GRF (1-29)**, omits that handle and clears in roughly 30 minutes. One is a slow multi-day background; the other is a brief pulse. Pairing a multi-day peptide with a short one means the actual GH exposure of a given protocol is not characterized — a real, not pedantic, caveat. The [cjc 1295 dac](/cjc-1295-dac) page walks the difference through with the pharmacokinetic traces. ## Cjc-1295 ipamorelin: what it is good for, in plain terms The studied and extrapolated endpoints cluster around the GH/IGF-1 axis: body composition, recovery, sleep architecture, and connective-tissue support. A 2026 meta-analysis of five randomized trials of the related GHRH analogue tesamorelin found significant reductions in visceral fat (mean difference −27.71 cm²) and liver fat (−4.28%), with a gain in lean mass (+1.42 kg) and no serious adverse events [7] — useful read-across for the GHRH arm, though tesamorelin is a different molecule. What CJC-1295 Ipamorelin does in humans as a fixed blend has not been measured directly. The honest framing throughout this review: it *raises* GH and IGF-1 (cited), and the downstream body-composition and recovery effects are studied for related compounds or reported anecdotally — never established human fact for this pair. The [CJC-1295 Ipamorelin research](/research) page lays out every study; the [cjc 1295 ipamorelin benefits](/benefits) page covers the reported upsides. ## How to read this site This is an editorial digest, not a clinic and not a shop. Every number on every page maps to a numbered citation you can open on [the references list](/references). Where the evidence is precise — the CJC-1295 half-life, the IGF-1 duration — we say so plainly. Where it is thin — human pharmacokinetics for ipamorelin, any data on the fixed blend — we leave the line openly unfilled rather than paper over it. Both compounds are prohibited in sport at all times under WADA Section S2 (peptide hormones and GH secretagogues). Neither is FDA-approved. Read the [CJC-1295 Ipamorelin effects](/effects) page for the reported benefits and the cited safety cautions before anything else. --- A calibrated reading of the CJC-1295 and ipamorelin literature — the measured findings logged to source, the untested fixed blend kept honestly apart, and the empty long-term-safety line left openly unfilled; not a clinic, not a vendor, not a prescription.